Comparison of Renal Adverse Events Between Intravitreal Anti-Vascular Endothelial Growth Factor Agents: A Meta-Analysis

Retinal Diseases

Effectiveness and Safety of Biosimilar Anti-Vascular Endothelial Growth Factor for Retinal Diseases: A Systematic Review and Meta-Analysis

Retina

Pandya BU, Mihalache A, Huang RS, Jhaveri A, Cao X, Ballios B, Felfeli T

doi: 10.1097/IAE.0000000000004807

Retinal Diseases

Anti-vascular endothelial growth factor and choroidal thickness in retinal vein occlusion: A systematic review and meta-analysis

Surv Ophthalmol

Sadek K, Yu P, Butt FR, Tao BK, Al-Ani A, Yeung S, Pereira A, Tang T, Arjmand P, Mishra A, Ing E, Yan P

doi: 10.1016/j.survophthal.2026.03.017

Macular Diseases

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Acta Ophthalmol

Falemban AH, Söderberg-Löfdal K, Jonsson F, Almlöf-Sarman S, von Euler M, Westborg I

doi: 10.1111/aos.17534

Macular DiseasesRetinal Diseases

Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis

Ophthalmol Retina

Lakhani M, Kwan ATH, Kundapur D, Popovic MM, Damji KF, Hurley BR

doi: 10.1016/j.oret.2025.08.018

Macular Diseases

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Acta Ophthalmol

Butler ETS, Arnold-Vangsted A, Schou MG, Anguita R, Bjerager J, Borrelli E, Cehofski LJ, Ferro Desideri L, van Dijk EHC, Faber C, Grauslund J, Hajari JN, Huemer J, Klefter ON, Krogh Nielsen M, Sabaner MC, Schneider M, Subhi Y

doi: 10.1111/aos.17506

Retinal Diseases

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis

JAMA Ophthalmol

Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, Scalco BG, Mattes NR, Lavinsky D, Kramer CK, Gerchman F

doi: 10.1001/jamaophthalmol.2025.2489

Further Publications

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

JAMA Ophthalmol

Bordbar DD, Mukhtar AO, Loya A, Alsoudi AF, Muayad J, Chauhan MZ, Patel NA, Sallam AB, Weng CY

doi: 10.1001/jamaophthalmol.2026.0460

Further Publications

Outcomes of Penetrating Keratoplasty vs Lamellar Endothelial Keratoplasty in Iridocorneal Endothelial Syndrome: A Systematic Review and Meta-Analysis

Am J Ophthalmol

Tóth G, Váncsa S, Kói T, Kormányos K, Hegyi P, Szentmáry N

doi: 10.1016/j.ajo.2025.04.017

Further Publications

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries

Ophthalmol Retina

Lakhani M, Popovic MM, Al-Ani A, Kundapur D, Gholamian T, Chaudry E, Nanji K, Patil N, Feo A, Sadda S, Sarraf D, Ip MS, Kertes PJ, Muni RH, Adatia F, Damji KF, Chaudhary V, Hurley BR

doi: 10.1016/j.oret.2025.10.019

Related content

Effectiveness and Safety of Biosimilar Anti-Vascular Endothelial Growth Factor for Retinal Diseases: A Systematic Review and Meta-Analysis

Anti-vascular endothelial growth factor and choroidal thickness in retinal vein occlusion: A systematic review and meta-analysis

Intravitreal anti-vascular endothelial growth factor injections and risks of stroke in patients with neovascular age-related macular degeneration-A registry-based cohort study

Association of Anti-VEGF Therapy with Reported Ocular Adverse Events: A Global Pharmacovigilance Analysis

Comparative efficacy of intravitreal anti-VEGF therapy for neovascular age-related macular degeneration: A systematic review with network meta-analysis

Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis

Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction

Outcomes of Penetrating Keratoplasty vs Lamellar Endothelial Keratoplasty in Iridocorneal Endothelial Syndrome: A Systematic Review and Meta-Analysis

Comparative Analysis of Ocular Adverse Events Associated with Aflibercept 8 mg and Faricimab: A Global Population-Based Study Across 65 Countries